The National Australian HCV Point-of-Care Testing Program - Minimal Dataset

Condition(s) studied

Investigational drug(s) / intervention(s)

Point-of-Care Testing: Participants will be offered finger-stick point-of-care testing for HCV

Study summary

The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). All participants who undergo HCV point-of-care testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.

Eligibility

Primary outcome measure(s)

• The proportion of HCV infected participants who initiate HCV treatment at 12 weeks — 12 Weeks from enrolment
  To evaluate the proportion of HCV infected (HCV RNA quantifiable) participants who initiate HCV treatment at 12 weeks following finger-stick point-of-care HCV RNA testing.

Trial sites (16)

More Kirby Institute trials in Australia

Other trials for the same condition